Background:

SARS-CoV-2 infection is linked to a variety of clinical symptoms, immunological dysfunction, and changes in the gut microbiota. Probiotics are live microbes that, when administered in adequate amounts, confer health benefits on their hosts. The intestinal microbiota, which may play a role in the defensive mechanisms against possible pathogens by fostering a wide variety of immune–host interactions, is influenced by the nutritional and biochemical quality of one’s food. This study, aims to find out the therapeutic value of administering probiotics to COVID-19 patients with regards to reduction of symptoms.

Methods:

An observation study was conducted among Covid-19 RT-PCR positive patients after getting informed consent. Total of 428 patients with or without symptomatic patients were included in this study. Probiotic dose of 120 millions CFU/ day was given to the covid-19 patients for minimum of 10days and maximum of 20 days, irrespetive of the severity of the disease. A semi-structured questionnaire was administered to obtain patients clinical history, comorbid conditions and sociodemographic details. Patients clinical conditions were compared after availing the treatment of probiotics.

Results:

In this cohort, 428 cases were enrolled after getting informed consent from the patients. After consuming 10 days of probiotics, almost 99.9 % recovered from the symptoms and 75% of them did not required O2 supply or ventilator and hospital admission. Only few have (2%) post covid symptoms like joint pain and guiddiness.

Conclusion:

Probiotics significantly reduced the clinical symptoms of critically ill COVID-19 patients. Probiotics may have a good supporting role in the treatment of patients with COVID-19 and its early application is recommended to prevent complications.